Evidence map›Paper›PMID 17325217›Full record

ArticleAntimicrobial agents and chemotherapy2007

Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Yseult F Brun, Carly G Dennis, William R Greco, Ralph J Bernacki, Paula J Pera, Jennifer J Bushey, Richard C Youn, Donald B White, Brahm H Segal

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yseult F BrunRoswell Park Cancer Institute, Buffalo, NY 14263, USA.
Carly G Dennis
William R Greco
Ralph J Bernacki
Paula J Pera
Jennifer J Bushey
Richard C Youn
Donald B White
Brahm H Segal

Funding

Concentration-time-effect modeling of agent combinationsR01RR010742 · NCRR · ROSWELL PARK CANCER INSTITUTE CORP · PI GRECO, WILLIAM ROBERT · 1994 to 2006
$1.2M
NCRR NIH HHS R01 RR010742NCRR NIH HHS RR10742
6 · The paper itself

Abstract

Response surface methods for the study of multiple-agent interaction allow one to model all of the information present in full concentration-effect data sets and to visualize and quantify local regions of synergy, additivity, and antagonism. In randomized wells of 96-well plates, Aspergillus fumigatus was exposed to various combinations of amphotericin B, micafungin, and nikkomycin Z. The experimental design was comprised of 91 different fixed-ratio mixtures, all performed in quintuplicate. After 24 h of drug exposure, drug effect on fungal viability was assessed using the tetrazolium salt 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide} (XTT) assay. First, we modeled each fixed-ratio combination alone using the four-parameter Hill concentration-effect model. Then, we modeled each parameter, including the 50% inhibitory concentration (IC(50)) effect, versus the proportion of each agent using constrained polynomials. Finally, we modeled the three-agent response surface overall. The overall four-dimensional response surface was complex, but it can be explained in detail both analytically and graphically. The grand model that fit the best included complex polynomial equations for the slope parameter m and the combination index (equivalent to the IC(50) for a fixed-ratio concentration, but with concentrations normalized by the respective IC(50)s of the drugs alone). There was a large region of synergy, mostly at the nikkomycin Z/micafungin edge of the ternary plots for equal normalized proportions of each drug and extending into the center of the plots. Applying this response surface method to a huge data set for a three-antifungal-agent combination is novel. This new paradigm has the potential to significantly advance the field of combination antifungal pharmacology.

Indexed as

AminoglycosidesAmphotericin BAntifungal AgentsAspergillus fumigatusConfidence IntervalsDrug CombinationsEchinocandinsLipopeptidesLipoproteinsMicafunginMicrobial Sensitivity TestsModels, StatisticalPeptides, CyclicAminoglycosidesAmphotericin BAntifungal AgentsDrug CombinationsEchinocandinsLipopeptidesLipoproteinsMicafunginnikkomycinPeptides, Cyclic

Identifiers

PMID17325217
PMCPMC1855564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.